Jan Pfeiffenberger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665504/publications.pdf

Version: 2024-02-01

623734 610901 32 634 14 24 g-index citations h-index papers 33 33 33 949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hepatobiliary malignancies in Wilson disease. Liver International, 2015, 35, 1615-1622.	3.9	78
2	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. British Journal of Cancer, 2019, 120, 109-114.	6.4	71
3	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). Journal of Hepatology, 2021, 75, 1346-1354.	3.7	69
4	Pregnancy in Wilson's disease: Management and outcome. Hepatology, 2018, 67, 1261-1269.	7.3	61
5	Iron metabolism and the role of <scp>HFE</scp> gene polymorphisms in <scp>W</scp> ilson disease. Liver International, 2012, 32, 165-170.	3.9	38
6	The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. Langenbeck's Archives of Surgery, 2018, 403, 719-731.	1.9	31
7	Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurology, 2017, 17, 140.	1.8	28
8	Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS ONE, 2019, 14, e0222771.	2.5	25
9	Longâ€term evaluation of urinary copper excretion and nonâ€caeruloplasmin associated copper in Wilson disease patients under medical treatment. Journal of Inherited Metabolic Disease, 2019, 42, 371-380.	3.6	23
10	Wilson disease: Health-related quality of life and risk for depression. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 349-356.	1.5	21
11	Nonâ€invasive diagnosis of cirrhosis and longâ€term disease monitoring by transient elastography in patients with Wilson disease. Liver International, 2020, 40, 894-904.	3.9	19
12	Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World Journal of Gastroenterology, 2019, 25, 1603-1617.	3.3	18
13	Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbeck's Archives of Surgery, 2013, 398, 1123-1128.	1.9	17
14	Concomitant immuneâ€related events in Wilson disease: implications for monitoring chelator therapy. Journal of Inherited Metabolic Disease, 2016, 39, 125-130.	3.6	15
15	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1033-1050.	2.5	14
16	Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 1692.	2.4	11
17	SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study. Transplantation Proceedings, 2021, 53, 1112-1117.	0.6	11
18	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointestinal Tumors, 2018, 5, 38-46.	0.7	8

#	Article	IF	Citations
19	Biliary Rhabdomyosarcoma in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. Frontiers in Oncology, 2021, 11, 701400.	2.8	8
20	Multidrug-Resistant Bacteria and Disease Progression in Patients with End-Stage Liver Disease and after Liver Transplantation. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 303-310.	0.9	8
21	The steady state pharmacokinetics of trientine in Wilson disease patients. European Journal of Clinical Pharmacology, 2018, 74, 731-736.	1.9	7
22	Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2761-2769.	2.5	7
23	Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World Journal of Gastroenterology, 2018, 24, 1353-1360.	3.3	7
24	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. Orphanet Journal of Rare Diseases, 2020, 15, 173.	2.7	6
25	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2471-2481.	2.5	6
26	Optimized Trientineâ€dihydrochloride Therapy in Pediatric Patients With Wilson Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 115-122.	1.8	6
27	Routine Liver Elastography Could Predict Actuarial Survival after Liver Transplantation. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 271-277.	0.9	5
28	Coagulation Parameters in Wilson Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 183-188.	0.9	5
29	Case report: a rare cause of a hypervascular nodule in a noncirrhotic liver. Zeitschrift Fur Gastroenterologie, 2019, 57, 57-60.	0.5	4
30	Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1269-1279.	3.7	4
31	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3163-3174.	2.5	3
32	Factors modifying phenotypic presentation in Wilson disease: authors' reply. Liver International, 2012, 32, 870-870.	3.9	0